| scholarly article | Q13442814 |
| P2093 | author name string | Michael J Nemeth | |
| Elizabeth A Griffiths | |||
| Benjamin E Paluch | |||
| Abdul R Naqash | |||
| Zachary Brumberger | |||
| P2860 | cites work | Gene number, noise reduction and biological complexity | Q40514856 |
| Preferential methylation of unmethylated DNA by Mammalian de novo DNA methyltransferase Dnmt3a. | Q40753457 | ||
| Role of Estrogen Receptor Gene Demethylation and DNA Methyltransferase·DNA Adduct Formation in 5-Aza-2′deoxycytidine-induced Cytotoxicity In Human Breast Cancer Cells | Q41070371 | ||
| Etiology, clinical course and outcome of healthcare-associated bloodstream infections in patients with hematological malignancies: a retrospective study of 350 patients in a Finnish tertiary care hospital | Q41153995 | ||
| De novo DNA cytosine methyltransferase activities in mouse embryonic stem cells | Q41161849 | ||
| Large conserved domains of low DNA methylation maintained by Dnmt3a | Q41946470 | ||
| Genome-wide regulation of 5hmC, 5mC, and gene expression by Tet1 hydroxylase in mouse embryonic stem cells | Q41960997 | ||
| Discrimination of Methylcytosine from Hydroxymethylcytosine in DNA Molecules | Q41977203 | ||
| Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations | Q42141882 | ||
| Cellular differentiation, cytidine analogs and DNA methylation | Q42242732 | ||
| The mechanism of inhibition of DNA (cytosine-5-)-methyltransferases by 5-azacytosine is likely to involve methyl transfer to the inhibitor | Q42272315 | ||
| Role of the DNA methyltransferase variant DNMT3b3 in DNA methylation. | Q42831709 | ||
| Enzymatic approaches and bisulfite sequencing cannot distinguish between 5-methylcytosine and 5-hydroxymethylcytosine in DNA. | Q43009515 | ||
| IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication | Q43010371 | ||
| Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment | Q44155422 | ||
| Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies | Q44646952 | ||
| Reading signals on the nucleosome with a new nomenclature for modified histones | Q45258400 | ||
| Epigenetic drugs: new modulators of readers and erasers | Q45788917 | ||
| 5-Methylcytosine as an Endogenous Mutagen in the Human LDL Receptor and p53 Genes | Q45943296 | ||
| Decitabine Enhances Lymphocyte Migration and Function and Synergizes with CTLA-4 Blockade in a Murine Ovarian Cancer Model. | Q45977893 | ||
| Trapped in action: direct visualization of DNA methyltransferase activity in living cells. | Q46717074 | ||
| Intertumor and intratumor NY-ESO-1 expression heterogeneity is associated with promoter-specific and global DNA methylation status in ovarian cancer | Q33715446 | ||
| Tissue distribution of 5-hydroxymethylcytosine and search for active demethylation intermediates | Q21089989 | ||
| Tiling resolution array CGH and high density expression profiling of urothelial carcinomas delineate genomic amplicons and candidate target genes specific for advanced tumors | Q21202038 | ||
| DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development | Q22010765 | ||
| The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain | Q22065852 | ||
| Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals | Q22122053 | ||
| Crystal structure of the nucleosome core particle at 2.8 Å resolution | Q22122355 | ||
| Dnmt3L cooperates with the Dnmt3 family of de novo DNA methyltransferases to establish maternal imprints in mice | Q24293298 | ||
| Selective inhibition of BET bromodomains | Q24301009 | ||
| Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1 | Q24316558 | ||
| Cancer-associated IDH1 mutations produce 2-hydroxyglutarate | Q24320239 | ||
| Histone demethylation mediated by the nuclear amine oxidase homolog LSD1 | Q24336747 | ||
| Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes | Q24338109 | ||
| The presence of 5-hydroxymethylcytosine in animal deoxyribonucleic acid | Q24531866 | ||
| A genome-wide analysis of CpG dinucleotides in the human genome distinguishes two distinct classes of promoters | Q24537436 | ||
| DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter | Q24554402 | ||
| Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study | Q24563021 | ||
| The MeCP1 complex represses transcription through preferential binding, remodeling, and deacetylating methylated nucleosomes | Q24602177 | ||
| The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate | Q24605258 | ||
| Mutation and cancer: statistical study of retinoblastoma | Q24618185 | ||
| The many roles of histone deacetylases in development and physiology: implications for disease and therapy | Q24628821 | ||
| Amount and distribution of 5-methylcytosine in human DNA from different types of tissues of cells | Q24632620 | ||
| Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases | Q24632807 | ||
| Human DNA methylomes at base resolution show widespread epigenomic differences | Q24633677 | ||
| Regulation of chromatin by histone modifications | Q24635070 | ||
| A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells | Q24635322 | ||
| Clinical implications of aberrant DNA methylation patterns in acute myelogenous leukemia | Q46758045 | ||
| Phenotypic and functional changes of human melanoma xenografts induced by DNA hypomethylation: immunotherapeutic implications | Q46776683 | ||
| The DNA demethylating agent 5-aza-2'-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma | Q46778780 | ||
| Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3-9. | Q46890994 | ||
| CpG sites preferentially methylated by Dnmt3a in vivo | Q46913515 | ||
| Molecular biology. Protein tail modification opens way for gene activity | Q46937473 | ||
| DNA hypomethylation and ovarian cancer biology. | Q47255043 | ||
| Genomic imprinting disrupted by a maternal effect mutation in the Dnmt1 gene | Q48371609 | ||
| The epigenotype. 1942. | Q48429495 | ||
| Dnmt3L and the Establishment of Maternal Genomic Imprints | Q48874297 | ||
| DNA methylation controls the inducibility of the mouse metallothionein-I gene in lymphoid cells | Q51256105 | ||
| Mammalian (cytosine-5) methyltransferases cause genomic DNA methylation and lethality in Drosophila | Q52573989 | ||
| Methylation of CpG sequences in eukaryotic DNA | Q70725576 | ||
| Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2'-deoxycytidine | Q72656874 | ||
| Effect of 5-azacytidine on differentiation and DNA methylation in human promyelocytic leukemia cells (HL-60) | Q72683682 | ||
| Mechanism of action of eukaryotic DNA methyltransferase. Use of 5-azacytosine-containing DNA | Q72693089 | ||
| Murine De Novo Methyltransferase Dnmt3a Demonstrates Strand Asymmetry and Site Preference in the Methylation of DNA In Vitro | Q77471629 | ||
| Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms | Q79734535 | ||
| Processive methylation of hemimethylated CpG sites by mouse Dnmt1 DNA methyltransferase | Q80918666 | ||
| Chemoproteomics quantifies complexity | Q83575955 | ||
| Tools and landscapes of epigenetics | Q84441692 | ||
| Differential effect of three base modifications on DNA thermostability revealed by high resolution melting | Q84770893 | ||
| Hydroxymethylation of DNA influences nucleosomal conformation and stability in vitro | Q85645100 | ||
| Further insights into the SAR of α-substituted cyclopropylamine derivatives as inhibitors of histone demethylase KDM1A | Q86522060 | ||
| Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies | Q24648438 | ||
| Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL) | Q24681480 | ||
| DNMT3A Mutations in Acute Myeloid Leukemia | Q27559610 | ||
| Inhibitor scaffolds for 2-oxoglutarate-dependent histone lysine demethylases | Q27652613 | ||
| Biochemical, structural, and biological evaluation of tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and LSD2 | Q27660798 | ||
| Adding a Lysine Mimic in the Design of Potent Inhibitors of Histone Lysine Methyltransferases | Q27661108 | ||
| Structurally designed trans-2-phenylcyclopropylamine derivatives potently inhibit histone demethylase LSD1/KDM1 | Q27662593 | ||
| Suppression of inflammation by a synthetic histone mimic | Q27665789 | ||
| Quantitative High-Throughput Screening Identifies 8-Hydroxyquinolines as Cell-Active Histone Demethylase Inhibitors | Q27666155 | ||
| Structural basis for CARM1 inhibition by indole and pyrazole inhibitors | Q27666983 | ||
| Inhibition of Histone Demethylases by 4-Carboxy-2,2′-Bipyridyl Compounds | Q27667281 | ||
| Small-Molecule Ligands of Methyl-Lysine Binding Proteins | Q27667285 | ||
| A Small Molecule Binding to the Coactivator CREB-Binding Protein Blocks Apoptosis in Cardiomyocytes | Q27667526 | ||
| Discovery and characterization of small molecule inhibitors of the BET family bromodomains | Q27667834 | ||
| Structural basis of substrate methylation and inhibition of SMYD2 | Q27670959 | ||
| Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia | Q27674674 | ||
| Contribution of histone N-terminal tails to the structure and stability of nucleosomes | Q27680641 | ||
| Synthesis, biological activity and mechanistic insights of 1-substituted cyclopropylamine derivatives: a novel class of irreversible inhibitors of histone demethylase KDM1A | Q27694826 | ||
| TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). | Q27851480 | ||
| Recurrent DNMT3A mutations in patients with myelodysplastic syndromes | Q27851629 | ||
| An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. | Q27852141 | ||
| The language of covalent histone modifications | Q27860931 | ||
| Histone demethylation by a family of JmjC domain-containing proteins | Q27939224 | ||
| Targeted mutation of the DNA methyltransferase gene results in embryonic lethality | Q28131773 | ||
| Genetic control of wing disc development in Drosophila | Q28139220 | ||
| A gene hypermethylation profile of human cancer | Q28213253 | ||
| Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy | Q28235397 | ||
| Histone deacetylases and cancer | Q28240447 | ||
| Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains | Q28242369 | ||
| BET bromodomain inhibition as a therapeutic strategy to target c-Myc | Q28247024 | ||
| DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia | Q28253465 | ||
| Decitabine and vorinostat cooperate to sensitize colon carcinoma cells to Fas ligand-induced apoptosis in vitro and tumor suppression in vivo | Q28263221 | ||
| An essential role for CoREST in nucleosomal histone 3 lysine 4 demethylation | Q28265681 | ||
| Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. | Q33716402 | ||
| Whole-genome analysis of 5-hydroxymethylcytosine and 5-methylcytosine at base resolution in the human brain. | Q33741993 | ||
| Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma. | Q33756997 | ||
| Rethinking how DNA methylation patterns are maintained | Q33763852 | ||
| Early aberrant DNA methylation events in a mouse model of acute myeloid leukemia | Q33772607 | ||
| Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features | Q33782633 | ||
| IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study | Q33897586 | ||
| Mechanisms of resistance to decitabine in the myelodysplastic syndrome. | Q33999539 | ||
| Protein lysine methyltransferase G9a inhibitors: design, synthesis, and structure activity relationships of 2,4-diamino-7-aminoalkoxy-quinazolines | Q34059822 | ||
| CpG island clusters and pro-epigenetic selection for CpGs in protein-coding exons of HOX and other transcription factors | Q34100309 | ||
| Dnmt3a and Dnmt1 functionally cooperate during de novo methylation of DNA. | Q34154656 | ||
| Differential methylation in CN-AML preferentially targets non-CGI regions and is dictated by DNMT3A mutational status and associated with predominant hypomethylation of HOX genes | Q34183388 | ||
| Dnmt3a is essential for hematopoietic stem cell differentiation | Q34237926 | ||
| Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma | Q34299814 | ||
| Base-pair resolution DNA methylation sequencing reveals profoundly divergent epigenetic landscapes in acute myeloid leukemia | Q34318280 | ||
| The Dnmt1 DNA-(cytosine-C5)-methyltransferase methylates DNA processively with high preference for hemimethylated target sites | Q34344734 | ||
| Clinical development of demethylating agents in hematology | Q34395179 | ||
| Selective small molecules blocking HIV-1 Tat and coactivator PCAF association | Q34396565 | ||
| Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia | Q34403931 | ||
| Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission | Q34405195 | ||
| DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. | Q34433577 | ||
| Assessing the underlying pattern of human germline mutations: lessons from the factor IX gene | Q34474779 | ||
| Structure-guided optimization of small molecules inhibiting human immunodeficiency virus 1 Tat association with the human coactivator p300/CREB binding protein-associated factor | Q34620638 | ||
| Sumoylated human histone H4 prevents chromatin compaction by inhibiting long-range internucleosomal interactions | Q34634124 | ||
| The novel, small-molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer. | Q34717933 | ||
| DNA methylation and chromatin - unraveling the tangled web. | Q34770498 | ||
| Modulating T-cell immunity to tumours: new strategies for monitoring T-cell responses | Q34791108 | ||
| The rate of hydrolytic deamination of 5-methylcytosine in double-stranded DNA | Q34811750 | ||
| The quantitative separation of purines, pyrimidines, and nucleosides by paper chromatography. | Q34854256 | ||
| Small-molecule ligands of methyl-lysine binding proteins: optimization of selectivity for L3MBTL3. | Q34990803 | ||
| A selective inhibitor and probe of the cellular functions of Jumonji C domain-containing histone demethylases | Q35097231 | ||
| Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML. | Q35164242 | ||
| Evaluation of azacitidine and entinostat as sensitization agents to cytotoxic chemotherapy in preclinical models of non-small cell lung cancer | Q35238397 | ||
| Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia | Q35533613 | ||
| Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology | Q28269080 | ||
| Regulation of LSD1 histone demethylase activity by its associated factors | Q28270391 | ||
| Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence | Q28277232 | ||
| Defining an epigenetic code | Q28281451 | ||
| The epigenomics of cancer | Q28289975 | ||
| The CpG dinucleotide and human genetic disease | Q28296311 | ||
| Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study | Q28301602 | ||
| A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines | Q28472733 | ||
| Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification | Q28504641 | ||
| Enzymatic properties of recombinant Dnmt3a DNA methyltransferase from mouse: the enzyme modifies DNA in a non-processive manner and also methylates non-CpG [correction of non-CpA] sites | Q28506872 | ||
| Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases | Q28507226 | ||
| Carboplatin with Decitabine Therapy, in Recurrent Platinum Resistant Ovarian Cancer, Alters Circulating miRNAs Concentrations: A Pilot Study | Q28550381 | ||
| The behaviour of 5-hydroxymethylcytosine in bisulfite sequencing | Q28749183 | ||
| Perceptions of epigenetics | Q29547310 | ||
| Methylation of lysine 4 on histone H3: intricacy of writing and reading a single epigenetic mark | Q29614516 | ||
| JmjC-domain-containing proteins and histone demethylation | Q29614517 | ||
| Histone H4-K16 acetylation controls chromatin structure and protein interactions | Q29614521 | ||
| Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer | Q29615066 | ||
| Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation | Q29615366 | ||
| DNA methylation and human disease | Q29615417 | ||
| Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia | Q29615735 | ||
| Epigenetic protein families: a new frontier for drug discovery | Q29616621 | ||
| Epigenetics: a landscape takes shape | Q29616623 | ||
| DNA methylation: roles in mammalian development | Q29616796 | ||
| Targeting MYC dependence in cancer by inhibiting BET bromodomains | Q29617196 | ||
| Gene silencing in cancer in association with promoter hypermethylation | Q29617274 | ||
| Linking DNA methylation and histone modification: patterns and paradigms | Q29617801 | ||
| Chromatin modification and epigenetic reprogramming in mammalian development | Q29617802 | ||
| Cytosine methylation and the ecology of intragenomic parasites | Q29618264 | ||
| Mutation in TET2 in myeloid cancers | Q29619292 | ||
| Charting histone modifications and the functional organization of mammalian genomes | Q29620707 | ||
| Impairment of prostate cancer cell growth by a selective and reversible lysine-specific demethylase 1 inhibitor | Q30414643 | ||
| Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase | Q33272939 | ||
| trans-2-Phenylcyclopropylamine is a mechanism-based inactivator of the histone demethylase LSD1. | Q33279148 | ||
| Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide). | Q33416734 | ||
| Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial | Q33417762 | ||
| Quantitative DNA methylation predicts survival in adult acute myeloid leukemia | Q33515724 | ||
| Comparative analysis of small molecules and histone substrate analogues as LSD1 lysine demethylase inhibitors | Q33530669 | ||
| DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes | Q33628772 | ||
| Decitabine immunosensitizes human gliomas to NY-ESO-1 specific T lymphocyte targeting through the Fas/Fas ligand pathway | Q35589288 | ||
| Characterization of in vitro and in vivo hypomethylating effects of decitabine in acute myeloid leukemia by a rapid, specific and sensitive LC-MS/MS method | Q35781849 | ||
| Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells | Q35851931 | ||
| Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer. | Q35860815 | ||
| Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer | Q35921697 | ||
| Tet family proteins and 5-hydroxymethylcytosine in development and disease | Q35944741 | ||
| A potential role for epigenetic modulatory drugs in the enhancement of cancer/germ-line antigen vaccine efficacy | Q35968482 | ||
| CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses | Q36008355 | ||
| The Pathogenesis of Mixed-Lineage Leukemia | Q36052947 | ||
| Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia. | Q36179524 | ||
| Clonal inheritance of the pattern of DNA methylation in mouse cells | Q36274408 | ||
| Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. | Q36303442 | ||
| Combination therapy with DNA methyltransferase inhibitors in hematologic malignancies | Q36338031 | ||
| DNA methylation and gene expression: endogenous retroviral genome becomes infectious after molecular cloning. | Q36383610 | ||
| Harnessing Noxa demethylation to overcome Bortezomib resistance in mantle cell lymphoma | Q36413767 | ||
| Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia | Q36515569 | ||
| Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells | Q36539785 | ||
| Accumulation and loss of asymmetric non-CpG methylation during male germ-cell development | Q36559178 | ||
| Discovery of a chemical probe for the L3MBTL3 methyllysine reader domain | Q36625174 | ||
| Genomic impact of transient low-dose decitabine treatment on primary AML cells | Q36654140 | ||
| Perceiving the epigenetic landscape through histone readers. | Q36821309 | ||
| Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AML. | Q36926120 | ||
| Non-CpG methylation is prevalent in embryonic stem cells and may be mediated by DNA methyltransferase 3a. | Q36967574 | ||
| Transcriptional plasticity promotes primary and acquired resistance to BET inhibition | Q37038076 | ||
| DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes | Q37052250 | ||
| Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. | Q37086937 | ||
| Chemical mechanisms of histone lysine and arginine modifications | Q37097824 | ||
| Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma | Q37164915 | ||
| Finding the fifth base: genome-wide sequencing of cytosine methylation. | Q37253268 | ||
| Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer | Q37338486 | ||
| Two DNA methyltransferases from murine erythroleukemia cells: purification, sequence specificity, and mode of interaction with DNA. | Q37348708 | ||
| Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. | Q37372837 | ||
| Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine | Q37420192 | ||
| BET bromodomain protein inhibition is a therapeutic option for medulloblastoma. | Q37420196 | ||
| The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. | Q37491118 | ||
| Superior sulcus tumors with vertebral body involvement: a multimodality approach | Q37493211 | ||
| Histone acetyltransferase inhibitors and preclinical studies | Q37497374 | ||
| Histone acetyl transferases as emerging drug targets. | Q37540911 | ||
| Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine | Q37576837 | ||
| Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer | Q37585487 | ||
| Protein methyltransferases as a target class for drug discovery | Q37590090 | ||
| Hydroxymethylation at gene regulatory regions directs stem/early progenitor cell commitment during erythropoiesis | Q37686349 | ||
| Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905. | Q37702336 | ||
| Therapy with azanucleosides for myelodysplastic syndromes | Q37765469 | ||
| 5-Hydroxymethylcytosine, the sixth base of the genome | Q37891924 | ||
| Epigenetic reprogramming in mouse pre-implantation development and primordial germ cells | Q37965513 | ||
| Molecular mechanisms and potential functions of histone demethylases | Q37999690 | ||
| Protein arginine methyltransferases and cancer | Q38067063 | ||
| X-Inactivation, Imprinting, and Long Noncoding RNAs in Health and Disease | Q38090112 | ||
| Histone lysine demethylases as targets for anticancer therapy | Q38162717 | ||
| New themes in the biological functions of 5-methylcytosine and 5-hydroxymethylcytosine. | Q38289020 | ||
| BET inhibitor resistance emerges from leukaemia stem cells | Q38835493 | ||
| Guadecitabine (SGI-110) priming sensitizes hepatocellular carcinoma cells to oxaliplatin | Q38854734 | ||
| Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts. | Q38952962 | ||
| BET bromodomain inhibition of MYC-amplified medulloblastoma. | Q39050679 | ||
| Nonpeptidic propargylamines as inhibitors of lysine specific demethylase 1 (LSD1) with cellular activity | Q39099941 | ||
| Immunomodulatory activity of SGI-110, a 5-aza-2'-deoxycytidine-containing demethylating dinucleotide. | Q39247530 | ||
| Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production | Q39458545 | ||
| MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing | Q39533432 | ||
| Enantioselective synthesis of tranylcypromine analogues as lysine demethylase (LSD1) inhibitors. | Q39580033 | ||
| Synthesis and biological activity of optically active NCL-1, a lysine-specific demethylase 1 selective inhibitor | Q39608783 | ||
| The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells | Q39716492 | ||
| Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers | Q39723644 | ||
| Identification of cell-active lysine specific demethylase 1-selective inhibitors | Q39768788 | ||
| Preference of DNA methyltransferases for CpG islands in mouse embryonic stem cells | Q39968046 | ||
| DNA methylation inhibitor 5-Aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B. | Q40054309 | ||
| P433 | issue | 4 | |
| P921 | main subject | epigenetics | Q26939 |
| P304 | page(s) | 285-295 | |
| P577 | publication date | 2016-02-26 | |
| P1433 | published in | Blood Reviews | Q15724415 |
| P1476 | title | Epigenetics: A primer for clinicians | |
| P478 | volume | 30 |
| Q38609772 | BET inhibitors: a novel epigenetic approach |
| Q42694831 | Bromodomain and Extraterminal Protein Inhibitor JQ1 Suppresses Thyroid Tumor Growth in a Mouse Model |
| Q49317837 | DNA Methylation Markers Improve the Sensitivity of Endoscopic Retrograde Cholangiopancreatography-Based Brushing Cytology in Extrahepatic Cholangiocarcinoma |
| Q37288310 | DNA methylation in spermatogenesis and male infertility |
| Q37729713 | Early-Life Nutritional Programming of Type 2 Diabetes: Experimental and Quasi-Experimental Evidence. |
| Q64065272 | Identification of a novel quinoline-based DNA demethylating compound highly potent in cancer cells |
| Q41642050 | Inhibition of histone deacetylase reduces transcription of NADPH oxidases and ROS production and ameliorates pulmonary arterial hypertension |
| Q52592339 | Leishmania amazonensis downregulates macrophage iNOS expression via Histone Deacetylase 1 (HDAC1): A novel parasite evasion mechanism. |
| Q47923445 | NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-Lymphocyte Responses in Patients with Myelodysplastic Syndrome |
| Q38810117 | Recent insights on the genetics and epigenetics of endometriosis |
| Q47867531 | The development and validation of EpiComet-Chip, a modified high-throughput comet assay for the assessment of DNA methylation status. |
| Q26746180 | The well-accepted notion that gene amplification contributes to increased expression still remains, after all these years, a reasonable but unproven assumption |
| Q41037623 | Wnt signalling meets epigenetics |
Search more.